menu
    • menu
    [{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SHP656","moa":"Cryptochrome circadian clock 1 (CRY1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Xenetic Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenetic Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xenetic Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Deoxyribonuclease I","moa":"||DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"Xenetic Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xenetic Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Xenetic Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"PeriNess","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"5-fluorouracil","moa":"||DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Xenetic Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenetic Biosciences \/ PeriNess","highestDevelopmentStatusID":"6","companyTruncated":"Xenetic Biosciences \/ PeriNess"},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sodium Cridanimod","moa":"Immune","graph1":"Oncology","graph2":"Phase II","graph3":"Xenetic Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenetic Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xenetic Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"PeriNess","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Agreement","leadProduct":"XBIO-015","moa":"NET","graph1":"Oncology","graph2":"IND Enabling","graph3":"Xenetic Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenetic Biosciences \/ PeriNess","highestDevelopmentStatusID":"5","companyTruncated":"Xenetic Biosciences \/ PeriNess"},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"PeriNess","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Collaboration","leadProduct":"XBIO-015","moa":"NET","graph1":"Oncology","graph2":"Preclinical","graph3":"Xenetic Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenetic Biosciences \/ PeriNess","highestDevelopmentStatusID":"4","companyTruncated":"Xenetic Biosciences \/ PeriNess"},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"VolitionRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Xenetic Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenetic Biosciences \/ VolitionRx","highestDevelopmentStatusID":"4","companyTruncated":"Xenetic Biosciences \/ VolitionRx"}]

    Find Clinical Drug Pipeline Developments & Deals by Xenetic Biosciences

    Menu

    Xenetic Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Xenetic Biosciences

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Xenetic Biosciences

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deoxyribonuclease I,Calcium Folinate,Fluorouracil

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : PeriNess

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xenetic Reports First Patient Dosed In DNase I + FOLFIRINOX Pancreatic Trial

                            Details : The exploratory clinical study of systemic DNase I in combination with FOLFIRINOX for the first line treatment of unresectable, locally advanced or metastatic pancreatic cancer.

                            Product Name : XBIO-015

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            July 08, 2025

                            Lead Product(s) : Deoxyribonuclease I,Calcium Folinate,Fluorouracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : PeriNess

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Xenetic Biosciences

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Xenetic Biosciences

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XBIO-015

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : PeriNess

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Xenetic, Partner Enter Clinical Study for DNase in Osteosarcoma, Ewing Sarcoma

                            Details : The collaboration aims to advance the clinical development of XBIO-015. It is being evaluated for the treatment of relapsed/refractory osteosarcoma and Ewing sarcoma.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            March 26, 2025

                            Lead Product(s) : XBIO-015

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : PeriNess

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Xenetic Biosciences

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Xenetic Biosciences

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deoxyribonuclease I,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xenetic Shows Preclinical Data on DNase I Boosting Immunotherapy Responses

                            Details : XBIO-020, a DNase I to be delivered to the tumor and secreted by CAR T therapies. It is being evaluated for the treatment of solid tumors.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            March 13, 2025

                            Lead Product(s) : Deoxyribonuclease I,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Xenetic Biosciences

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Xenetic Biosciences

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XBIO-015

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : PeriNess

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Xenetic Enters Agreement with PeriNess for DNase I Oncology Program Development

                            Details : Under the agreement, Xenetic aims to advance the development program, XBIO-015 in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            December 05, 2024

                            Lead Product(s) : XBIO-015

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : PeriNess

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Xenetic Biosciences

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Xenetic Biosciences

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : VolitionRx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limi...

                            Details : Under the terms of the collaboration agreement, Volition will fund a research program and the two parties will share proceeds from commercialization or licensing of any products arising from the collaboration.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 11, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : VolitionRx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Xenetic Biosciences

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Xenetic Biosciences

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SHP656

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xenetic Biosciences (XBIO) Announces Publication of Data from Partner's Phase 1/2 Study Evaluating Program Lev...

                            Details : The results from this single-dose study indicate that polysialylation of rFVIII confers a half-life extension similar to that of approved extended half-life products that use PEG or Fc fusion.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 14, 2020

                            Lead Product(s) : SHP656

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Xenetic Biosciences

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Xenetic Biosciences

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Cridanimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer

                            Details : Sodium Cridanimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Endometrial Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 13, 2017

                            Lead Product(s) : Sodium Cridanimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth